The U.S. Food and Drug Administration (FDA) has told compounders directly that semaglutide sodium and semaglutide acetate, the salt forms some pharmacies substituted for semaglutide base once the injectable came off the drug shortage list, are different active ingredients than the ingredient used in FDA's approved semaglutide products. FDA has stated it is not aware of any lawful basis for compounding with these salts under 503A/503B. A pharmacy still dispensing a salt-form product labeled simply as semaglutide is compounding an active ingredient the agency has already flagged, and the exposure runs from a misbranding finding to a state board of pharmacy complaint to civil liability from patients who never learned they received a substitute.
Base Semaglutide and Salt Forms Are Not the Same Active Ingredient
FDA's approved semaglutide injectables use the base form of the molecule. In its public safety communication on unapproved GLP-1 drugs, FDA states that salt forms should not be used to compound semaglutide, that products described as semaglutide sodium and semaglutide acetate are different active ingredients than the ones in the approved drugs, and that the agency lacks information showing these salts share the chemical and pharmacologic properties of the approved active ingredient. FDA raised the same concern earlier, notifying the National Association of Boards of Pharmacy on April 27, 2023 that it was not aware of any basis for compounding with the salts that would satisfy federal bulk drug substance requirements.
Why Salt Forms Fail the Bulk Substance Requirements
Compounding with a bulk drug substance under 503A requires the substance to meet a USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on the agency's 503A bulks list. Outsourcing facilities compounding under 503B face the parallel bulks-list requirement on top of cGMP obligations. Semaglutide lacks a USP or NF monograph. Semaglutide base clears the second prong because it is a component of an approved drug. Semaglutide sodium and semaglutide acetate clear none of the three: they are not components of any approved drug, and neither salt appears on a bulks list. The Mississippi Board of Pharmacy has told licensees in writing that semaglutide salt compounding does not meet FDA's bulk substance requirements and may draw action from FDA or the board itself.
The Shortage That Justified Compounding Is Over
Compounding a copy of an approved drug is ordinarily prohibited, but the shortage exception built into 503A and 503B let compounders fill the gap while semaglutide sat on FDA's drug shortage list. FDA resolved that shortage in a February 21, 2025 declaratory order, giving state-licensed pharmacies until April 22, 2025 and registered outsourcing facilities until May 22, 2025 to stop relying on the shortage exception. Once those wind-down windows closed, the shortage-based justification for compounding semaglutide in any form disappeared, taking the one argument that had briefly made the salt-form substitution colorable with it. Our companion piece on semaglutide compounding after the shortage delisting covers the wind-down deadlines in more detail.
Semaglutide sodium and semaglutide acetate are different active ingredients than the base form in FDA's approved products, and FDA has said it is not aware of any lawful basis for compounding with them.
Enforcement Since the Shortage Ended
FDA sent more than 50 warning letters to GLP-1 compounders and online sellers on September 9, 2025, citing misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act for marketing claims telling patients a compounded product carried the same active ingredient as FDA's approved semaglutide injectables. State boards of pharmacy have issued parallel warnings. New Jersey's board has told licensees the salt form may not be used in compounding at all, even when semaglutide base is sourced from an FDA-registered facility with a valid certificate of analysis. A pharmacy facing a state board compounding inspection over salt-form dispensing, or handling a related peptide compounding inquiry, is answering to both regulators at once.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacists promptly retain experienced healthcare defense counsel upon receiving an FDA warning letter, a state board of pharmacy inquiry, or any other government notice tied to semaglutide salt compounding. Early legal intervention can protect the pharmacy's rights, ensure the response addresses both the bulk substance question and any labeling or marketing claims at issue, avoid inadvertent admissions, and preserve defenses that may otherwise be lost. Delaying representation can significantly affect the outcome of the matter.
How Health Law Alliance Can Help
Health Law Alliance defends compounding pharmacies nationwide against FDA warning letters and state board of pharmacy actions tied to semaglutide and other GLP-1 compounding, including the 503A/503B bulk substance determinations that turn a salt-form dispensing pattern into a licensure matter. If your pharmacy has received a warning letter or board inquiry involving semaglutide salt forms, contact us for a free, confidential consultation.
